Want the real keys to longevity? Pay attention to these 3 critical numbers at your next physical

 I barely do and don't care, worry about these isn't going to extend my joyful life one bit.

Want the real keys to longevity? Pay attention to these 3 critical numbers at your next physical

There is no silver bullet to ensuring a longer, healthier life (and no single supplement, treatment, or hack). Rather, longevity is a complex interplay between genetics, lifestyle, environment, access to health care, and pure luck. But one top longevity doctor says there’s a great way to increase your odds of seeing your 100th birthday: Fight back against chronic conditions like type 2 diabetes, heart disease, cancer, and Alzheimer’s or other dementias.

“Preventing chronic disease can extend the number of healthy years people have,” says David Dodick, MD, a neurologist and the chief science and medical officer at Atria Health + Research Institute. “We’re preventing diseases that will kill them sooner.”

There are lots of daily habits that can help you slash your risk of chronic disease, and we bet you’re familiar with the greatest hits: eating a nutritious diet, exercising regularly, prioritizing sleep, and reducing stress. But Dr. Dodick says that there are three key numbers that can forecast your risk level and signal that it’s time to make healthy changes before disaster strikes. And they’re found at your annual physical.

Intrigued? Dr. Dodick shares the metrics you should pay attention to on your next doctor’s visit—and why they matter so much for long-term health.

1. Blood Pressure

Why it matters: Your blood pressure—the force of your blood pushing against your arteries—is a key sign of your cardiovascular health. High blood pressure, known as hypertension, is a major risk factor for stroke, heart attack, and dementia, says Dr. Dodick. While about half of all American adults have hypertension, not all of them are properly getting treated for it, he adds.

 Related video: Things you didn't know about metformin and longevity that could change your health (Talking With Docs)Your ideal range: You want your blood pressure consistently below 120/80 mm Hg, says Dr. Dodick. (And we mean both the top and bottom numbers.) Stage 1 hypertension is diagnosed with a blood pressure reading of

130/80 mm Hg or higher, per the American Heart Association (AHA).

2. Blood Sugar (A1C)

Why it matters: Type 2 diabetes is an incredibly common chronic disease in the U.S., says Dr. Dodick, and can raise your risk of developing dementia, chronic kidney disease, cardiovascular disease, and other serious health issues. The condition doesn’t happen overnight; it manifests slowly in your blood work in the form of ever-higher blood glucose (sugar) and hemoglobin A1C scores. (The latter denotes the average amount of blood sugar in the previous three months, and is reported as a percentage.)

Your ideal range: While a normal A1C is anything under 5.7 percent, Dr. Dodick says that an optimal score is less than 5.5 percent. “The lower your A1C, the healthier you’re going to be,” he says. Meanwhile, prediabetes is defined by a score of 5.7 to 6.4 percent, and diabetes is 6.5 percent or greater.

3. LDL Cholesterol

Why it matters: Despite its “bad” moniker, your body needs moderate amounts of low-density lipoprotein (LDL) cholesterol to move cholesterol and other lipids through your bloodstream to your cells. But too much of it contributes to plaque buildup in your arteries and is one of the main risk factors for cardiovascular disease and dementia, says Dr. Dodick.

Your ideal range: Dr. Dodick likes his patients to have an LDL of less than 90 mg/dL—a slightly more aggressive number than the AHA’s recommendation of less than 100 mg/dL.

Hate Your Numbers? What to Do Next

It can be scary when your labs reveal issues, even if they’re small. Thankfully, there’s a lot you can do now to improve your numbers and curb your risk of serious health issues in the future. Your doctor can offer specific recommendations, but these are a great starting point:

• Tweak your diet: We’ve said it once, we’ll say it again: Have you considered the Mediterranean diet? It’s flexible, delicious, and linked with reduced weight, blood pressure, cholesterol levels, and diabetes risk.(The Mediterranean diet has NO specifics, so you don't even know if you are following it correctly!)
• Move daily: Exercise isn’t just good for your heart health; it’s also critical for reducing diabetes risk and boosting your cognitive health. While 150 minutes a week of moderate-intensity activity, plus two days a week of strength training, is the gold standard, even five-minute “exercise snacks” can make a difference.
• Eat more fiber: Fiber: It’s not just for gut health. According to the National Lipid Association, eating 5 to 10 grams of soluble fiber a day can help lower total and LDL cholesterol by up to 11 points. If Metamucil makes you sad, add more helpings of foods like berries, apples, and lentils.
• Find some peace: Easier said than done in 2026. But unmitigated stress wreaks havoc on your blood pressure and glucose levels and is linked to various chronic diseases. Make time every day for meditation, yoga, embroidery, puzzling, or any other mindful activity that helps you recenter.(Retirement took care of that and dumping the ex.)
• Consider medication: Sometimes, all the lifestyle changes in the world can’t compensate for your unique genetic wiring. That’s where meds enter the picture. Talk to your doctor about your options and when they think a prescription would be necessary.

Want the real keys to longevity? Pay attention to these 3 critical numbers at your next physical

1.  Blood pressure is treated but don't care about perfection.
2. No clue on blood sugar
3. Not worrying about cholesterol, taking statins, so there.

Want the real keys to longevity? Pay attention to these 3 critical numbers at your next physical

There is no silver bullet to ensuring a longer, healthier life (and no single supplement, treatment, or hack). Rather, longevity is a complex interplay between genetics, lifestyle, environment, access to health care, and pure luck. But one top longevity doctor says there’s a great way to increase your odds of seeing your 100th birthday: Fight back against chronic conditions like type 2 diabetes, heart disease, cancer, and Alzheimer’s or other dementias.

“Preventing chronic disease can extend the number of healthy years people have,” says David Dodick, MD, a neurologist and the chief science and medical officer at Atria Health + Research Institute. “We’re preventing diseases that will kill them sooner.”

There are lots of daily habits that can help you slash your risk of chronic disease, and we bet you’re familiar with the greatest hits: eating a nutritious diet, exercising regularly, prioritizing sleep, and reducing stress. But Dr. Dodick says that there are three key numbers that can forecast your risk level and signal that it’s time to make healthy changes before disaster strikes. And they’re found at your annual physical.

Intrigued? Dr. Dodick shares the metrics you should pay attention to on your next doctor’s visit—and why they matter so much for long-term health.

1. Blood Pressure

Why it matters: Your blood pressure—the force of your blood pushing against your arteries—is a key sign of your cardiovascular health. High blood pressure, known as hypertension, is a major risk factor for stroke, heart attack, and dementia, says Dr. Dodick. While about half of all American adults have hypertension, not all of them are properly getting treated for it, he adds.

 Related video: The six pillars of longevity most people ignore (KFMB San Diego)

Your ideal range: You want your blood pressure consistently below 120/80 mm Hg, says Dr. Dodick. (And we mean both the top and bottom numbers.) Stage 1 hypertension is diagnosed with a blood pressure reading of 130/80 mm Hg or higher, per the American Heart Association (AHA).

2. Blood Sugar (A1C)

Why it matters: Type 2 diabetes is an incredibly common chronic disease in the U.S., says Dr. Dodick, and can raise your risk of developing dementia, chronic kidney disease, cardiovascular disease, and other serious health issues. The condition doesn’t happen overnight; it manifests slowly in your blood work in the form of ever-higher blood glucose (sugar) and hemoglobin A1C scores. (The latter denotes the average amount of blood sugar in the previous three months, and is reported as a percentage.)

Your ideal range: While a normal A1C is anything under 5.7 percent, Dr. Dodick says that an optimal score is less than 5.5 percent. “The lower your A1C, the healthier you’re going to be,” he says. Meanwhile, prediabetes is defined by a score of 5.7 to 6.4 percent, and diabetes is 6.5 percent or greater.

3. LDL Cholesterol

Why it matters: Despite its “bad” moniker, your body needs moderate amounts of low-density lipoprotein (LDL) cholesterol to move cholesterol and other lipids through your bloodstream to your cells. But too much of it contributes to plaque buildup in your arteries and is one of the main risk factors for cardiovascular disease and dementia, says Dr. Dodick.

Your ideal range: Dr. Dodick likes his patients to have an LDL of less than 90 mg/dL—a slightly more aggressive number than the AHA’s recommendation of less than 100 mg/dL.

Hate Your Numbers? What to Do Next

It can be scary when your labs reveal issues, even if they’re small. Thankfully, there’s a lot you can do now to improve your numbers and curb your risk of serious health issues in the future. Your doctor can offer specific recommendations, but these are a great starting point:

• Tweak your diet: We’ve said it once, we’ll say it again: Have you considered the Mediterranean diet? It’s flexible, delicious, and linked with reduced weight, blood pressure, cholesterol levels, and diabetes risk.
• Move daily: Exercise isn’t just good for your heart health; it’s also critical for reducing diabetes risk and boosting your cognitive health. While 150 minutes a week of moderate-intensity activity, plus two days a week of strength training, is the gold standard, even five-minute “exercise snacks” can make a difference.
• Eat more fiber: Fiber: It’s not just for gut health. According to the National Lipid Association, eating 5 to 10 grams of soluble fiber a day can help lower total and LDL cholesterol by up to 11 points. If Metamucil makes you sad, add more helpings of foods like berries, apples, and lentils.
• Find some peace: Easier said than done in 2026. But unmitigated stress wreaks havoc on your blood pressure and glucose levels and is linked to various chronic diseases. Make time every day for meditation, yoga, embroidery, puzzling, or any other mindful activity that helps you recenter.
• Consider medication: Sometimes, all the lifestyle changes in the world can’t compensate for your unique genetic wiring. That’s where meds enter the picture. Talk to your doctor about your options and when they think a prescription would be necessary.

Intensive blood pressure-lowering cut recurrent stroke risk by around 38% after brain haemorrhage

 

Your doctor obviously hasn't thought  through blood pressure at all. Lowering too much means the penumbra will die quicker because of lack of oxygenated blood. Can't your competent? doctor think at all about how to get you recovered?

Intensive blood pressure-lowering cut recurrent stroke risk by around 38% after brain haemorrhage

Intensive, long-term blood pressure-lowering treatment reduced the risk of recurrent stroke by 38%, without increasing serious adverse events(Is not recovering a serious adverse event because you allowed vastly more neurons to die, due to lack of blood and oxygen?), in people who have survived an intracerebral haemorrhage (ICH). The findings of the major meta-analysis were published today in The Lancet Neurology.

Researchers analysed data from four randomised controlled trials involving 2,944 adults with ICH. Two studies investigated fixed-dose antihypertensive therapies and two evaluated treatment strategies based on defined blood pressure targets.

During a follow-up period of up to six years, recurrent stroke of any type occurred in 6.5% of patients receiving intensive blood pressure-lowering compared with 10.4% of those receiving less intensive treatment or standard care (the control arm). This translated to a 38% reduction in recurrent stroke risk, with consistent benefits observed across all studies.

Professor Craig Anderson, senior author and Senior Professorial Fellow at The George Institute said the findings provide compelling evidence for more intensive blood pressure management after ICH.

“Intracerebral haemorrhage is one of the deadliest forms of stroke, with limited treatment options and a high risk of recurrence among survivors. Our analysis shows that intensive blood pressure treatment can prevent 16 recurrent strokes for every 1,000 patients treated within the first year alone. These findings reinforce the central role of blood pressure control in secondary stroke prevention.”

During follow-up, average systolic blood pressure (SBP) was 127 mm Hg in the intensive treatment group and 138 mm Hg in the control group, representing a mean difference of 11.2 mm Hg.

The reduction in recurrent stroke was mainly driven by an approximately 61% lower risk of ICH among patients receiving intensive treatment. Importantly, there was no observed increase in serious adverse events, which occurred in approximately 29% of patients in the intensive treatment group and 33% of patients receiving standard care.

The findings have important global implications. More than three million people experience ICH each year and there’s an estimated 17 million survivors.2 Among these survivors, approximately one quarter will later die from recurrent stroke or cardiovascular disease.3

The ICH burden falls disproportionately on low- and middle-income countries, where high blood pressure is often inadequately controlled.4 Rates of ICH are almost twice as high in these countries compared with high-income nations.4

Subgroup analysis showed that the benefits of intensive blood pressure lowering were consistent regardless of how much time had passed since the initial ICH event.

Effects were consistent across different baseline blood pressure levels. Notably, patients whose baseline blood pressure was already at conventional target remained at considerable risk and benefitted from blood pressure lowering. For example, among those with systolic blood pressure ≤130 mm Hg at baseline, recurrent stroke occurred in 13.9% of control patients compared with 6.2% of patients receiving intensive treatment.

Professor Anderson added that the findings challenge assumptions made by current guidelines.

“Generally, guidelines recommend treatment to a target of less than 130/80 mm Hg, but our study showed that patients at or below this threshold can still face a significant risk of recurrent stroke.”

“Preventing stroke recurrence requires us to address the persistent barriers to blood pressure control, such as poor treatment adherence and therapeutic inertia. To achieve reliable control, we need to continue pursuing approaches that have shown promise, including fixed-dose combination therapies and structured treatment titration protocols.”

The TRIDENT study, led by The George Institute for Global Health, was the only trial in this analysis that exclusively enrolled patients with spontaneous ICH. The remaining trials included people with either ischaemic stroke or ICH at baseline.

---

Journal

The Lancet Neurology

Method of Research

Meta-analysis

Subject of Research

People

Article Title

Intensive blood pressure lowering after spontaneous intracerebral haemorrhage for secondary stroke prevention (RECAP-ICH): a systematic review and individual participant data meta-analysis

Article Publication Date

12-Aug-2026

The Daily Habit That May Be One Of The Best Ways To Protect Your Heart by mindboygreen

 Interesting that they very specifically tell you the optimum number of steps to do; 7,126. Did your competent? doctor get you recovered enough to do that? NO? So, PURE INCOMPETENCE FROM YOUR DOCTOR! Fired yet? In the business world a fireable offense is not meeting client goals! And the only goal in stroke is 100% recovery; don't allow your medical staff to suggest anything less!

The Daily Habit That May Be One Of The Best Ways To Protect Your Heart

Toward a paradigm shift in post-stroke management

 Better late than never in coming to the conclusion that blood pressure management is a complete shitshow! Wrong objective! Had you been thinking at all you would be solving the  5 causes of the neuronal cascade of death in the first week saving hundreds of million to billions of neurons!

Toward a paradigm shift in post-stroke management

 New HOPE trial explores individualized approach based on reperfusion pathophysiology. Blood pressure management after thrombectomy for acute ischemic stroke may require a change in approach. The HOPE clinical trial—short for Hemodynamic Optimization of Cerebral Perfusion after Endovascular Therapy—led by the Sant Pau Research Institute (IR Sant Pau), has shown that adapting blood pressure targets to the degree of cerebral reperfusion significantly improves patients’ functional recovery without increasing the risk of complications.  “Until now, we have applied fairly uniform strategies after thrombectomy, but probably not all patients need the same approach,” says Dr. Pol Camps-Renom, head of the Cerebrovascular Diseases Research Group at IR Sant Pau and one of the study coordinators. “Our results suggest that adjusting blood pressure according to the degree of reperfusion can have a direct impact on recovery.” The findings, presented during a plenary session at the annual European Stroke Organisation conference—the leading European scientific society dedicated to stroke—and now published in JAMA Neurology position this work among the most important recent contributions in the stroke field. They have the potential to guide new hemodynamic management strategies after thrombectomy.  Rather than applying rigid targets, the key is to better understand each patient's physiologyPol Camps-Renom

Mechanical thrombectomy has been a major advance in the treatment of large-vessel occlusion stroke because it can restore blood flow in previously blocked arteries. However, a well-known paradox remains in clinical practice: despite successful angiographic reperfusion, a substantial proportion of patients—around half—do not achieve satisfactory functional recovery in the medium term. 

This phenomenon, known as “clinically ineffective reperfusion,” reflects the fact that reopening the vessel does not always result in effective restoration of cerebral perfusion at the tissue level. Mechanisms involved include reperfusion injury, microcirculatory dysfunction, loss of cerebral autoregulation, and hemorrhagic transformation, all of which can compromise brain tissue viability even after a technically successful intervention. 

“Many times we can reopen the artery, but the brain tissue does not respond as expected,” explains Dr. Pol Camps-Renom. “The reason is that microvascular perfusion and autoregulatory mechanisms may be impaired, and this is where factors such as blood pressure become critical.” (You blithering idiots are ignoring the neuronal cascade of death in the first week and thus letting die hundreds of millions to billions of neurons! No wonder stroke recovery never gets better with this level of absolute stupidity in not knowing why artery opening doesn't solve the problem!)

 

As a result, blood pressure control during the hours following thrombectomy has become a key component of clinical management because it directly influences the balance between maintaining adequate perfusion and avoiding hemorrhagic complications. However, the evidence available so far has been limited and, at times, contradictory. Previous trials based on uniform intensive blood pressure reduction strategies have not demonstrated consistent benefits and have even suggested possible adverse effects. 

The HOPE trial introduces a different approach based on the concept that hemodynamic management should be adapted to each patient's physiological condition after thrombectomy. The study included 440 patients treated at 11 Spanish hospitals, who were randomly assigned either to a conventional strategy or to blood pressure management tailored to the degree of reperfusion achieved. 

Unlike previous trials, HOPE implemented a differentiated strategy according to the final angiographic result. Patients with near-complete or complete reperfusion were treated with lower blood pressure targets to reduce the risk of reperfusion injury, whereas patients with incomplete reperfusion maintained higher blood pressure levels to preserve cerebral perfusion. 

This approach recognizes that the brain may be in extremely diverse hemodynamic states, in which both excessively high blood pressure and overly aggressive reductions can be harmful. For this reason, the protocol included close monitoring during the first 72 hours, with dynamic treatment adjustments. 

This strategy resulted in a significant and consistent improvement in clinical outcomes. At 90 days, 60.0% of patients in the intervention group achieved functional independence, compared with 47.1% in the control group, representing an absolute difference of 13.3 percentage points, a clinically meaningful improvement. In addition, the overall analysis showed a favorable trend toward better levels of recovery, reinforcing the consistency of the benefit. 

In terms of safety, the strategy was associated with a lower incidence of hemorrhagic transformation, without increasing mortality or serious complications, confirming a favorable balance between efficacy and safety. “We have shown that it is possible to improve patient recovery without adding risk,” adds Dr. Joan Martí-Fàbregas, another investigator involved in the study. “This balance between efficacy and safety is probably one of the most relevant aspects of the findings.” 

The results of the HOPE trial point toward a more individualized model for blood pressure control after thrombectomy. In a setting where previous trials had produced neutral or unfavorable results, this study introduces a physiology-based approach that can optimize the balance between perfusion and hemorrhagic risk. 

Beyond its findings, HOPE provides key elements for the design of future studies, including the stratification of therapeutic targets and prolonged hemodynamic monitoring. The study also reinforces the idea that stroke treatment does not end with recanalization but continues during the hours that follow. “Rather than applying rigid targets, the key is to better understand each patient's physiology,” concludes Dr. Camps-Renom. 

Although the trial was stopped before reaching the planned sample size, its results demonstrate a clinically meaningful effect size. Nevertheless, additional studies will be required to confirm these findings before they can be broadly incorporated into routine clinical practice. 

Overall, the HOPE trial positions blood pressure control as a key component in optimizing stroke treatment after thrombectomy and opens the door to more precise strategies tailored to individual patients. 

Source: Institut de Recerca Sant Pau 

Blood pressure control may be the key to optimizing stroke treatment after thrombectomy

How the hell are you objectively measuring reperfusion success? I've seen a lot of reports that declared reperfusion a failure because the patient didn't recover. You blithering idiots are ignoring the neuronal cascade of death in the first week and thus letting die hundreds of millions to billions of neurons! No wonder stroke recovery never gets better with this level of stupidity!

 Blood pressure control may be the key to optimizing stroke treatment after thrombectomy

Blood pressure management after thrombectomy for acute ischemic stroke may require a change in approach. The HOPE clinical trial-short for Hemodynamic Optimization of Cerebral Perfusion after Endovascular Therapy-led by the Sant Pau Research Institute (IR Sant Pau), has shown that adapting blood pressure targets to the degree of cerebral reperfusion significantly improves patients' functional recovery without increasing the risk of complications.

Until now, we have applied fairly uniform strategies after thrombectomy, but probably not all patients need the same approach. Our results suggest that adjusting blood pressure according to the degree of reperfusion can have a direct impact on recovery."

Dr. Pol Camps-Renom, head of the Cerebrovascular Diseases Research Group at IR Sant Pau and one of the study coordinators

The findings, presented during a plenary session at the annual European Stroke Organisation conference-the leading European scientific society dedicated to stroke-and now published in JAMA Neurology position this work among the most important recent contributions in the stroke field. They have the potential to guide new hemodynamic management strategies after thrombectomy.

Reopening the artery does not always translate into recovery

Mechanical thrombectomy has been a major advance in the treatment of large-vessel occlusion stroke because it can restore blood flow in previously blocked arteries. However, a well-known paradox remains in clinical practice: despite successful angiographic reperfusion, a substantial proportion of patients-around half-do not achieve satisfactory functional recovery in the medium term.(Really? you don't know about the 

the neuronal cascade of death in the first week killing off hundreds of millions to billions of neurons! You're that stupid?)

This phenomenon, known as "clinically ineffective reperfusion," reflects the fact that reopening the vessel does not always result in effective restoration of cerebral perfusion at the tissue level. Mechanisms involved include reperfusion injury, microcirculatory dysfunction, loss of cerebral autoregulation, and hemorrhagic transformation, all of which can compromise brain tissue viability even after a technically successful intervention.

"Many times we can reopen the artery, but the brain tissue does not respond as expected," explains Dr. Pol Camps-Renom. "The reason is that microvascular perfusion and autoregulatory mechanisms may be impaired, and this is where factors such as blood pressure become critical."

As a result, blood pressure control during the hours following thrombectomy has become a key component of clinical management because it directly influences the balance between maintaining adequate perfusion and avoiding hemorrhagic complications. However, the evidence available so far has been limited and, at times, contradictory. Previous trials based on uniform intensive blood pressure reduction strategies have not demonstrated consistent benefits and have even suggested possible adverse effects.

An individualized approach based on reperfusion physiology

The HOPE trial introduces a different approach based on the concept that hemodynamic management should be adapted to each patient's physiological condition after thrombectomy. The study included 440 patients treated at 11 Spanish hospitals, who were randomly assigned either to a conventional strategy or to blood pressure management tailored to the degree of reperfusion achieved.

Unlike previous trials, HOPE implemented a differentiated strategy according to the final angiographic result. Patients with near-complete or complete reperfusion were treated with lower blood pressure targets to reduce the risk of reperfusion injury, whereas patients with incomplete reperfusion maintained higher blood pressure levels to preserve cerebral perfusion.

A guide to advancing biotherapeutic research eBook Welcome to your essential guide to advancing biotherapeutic research.Download the latest edition

This approach recognizes that the brain may be in extremely diverse hemodynamic states, in which both excessively high blood pressure and overly aggressive reductions can be harmful. For this reason, the protocol included close monitoring during the first 72 hours, with dynamic treatment adjustments.

Better functional recovery without increased complications

This strategy resulted in a significant and consistent improvement in clinical outcomes. At 90 days, 60.0% of patients in the intervention group achieved functional independence, compared with 47.1% in the control group, representing an absolute difference of 13.3 percentage points, a clinically meaningful improvement. In addition, the overall analysis showed a favorable trend toward better levels of recovery, reinforcing the consistency of the benefit.

In terms of safety, the strategy was associated with a lower incidence of hemorrhagic transformation, without increasing mortality or serious complications, confirming a favorable balance between efficacy and safety. "We have shown that it is possible to improve patient recovery without adding risk," adds Dr. Joan Martí-Fàbregas, another investigator involved in the study. "This balance between efficacy and safety is probably one of the most relevant aspects of the findings."

Toward a paradigm shift in post-stroke management

The results of the HOPE trial point toward a more individualized model for blood pressure control after thrombectomy. In a setting where previous trials had produced neutral or unfavorable results, this study introduces a physiology-based approach that can optimize the balance between perfusion and hemorrhagic risk.

Beyond its findings, HOPE provides key elements for the design of future studies, including the stratification of therapeutic targets and prolonged hemodynamic monitoring. The study also reinforces the idea that stroke treatment does not end with recanalization but continues during the hours that follow. "Rather than applying rigid targets, the key is to better understand each patient's physiology," concludes Dr. Camps-Renom.

Although the trial was stopped before reaching the planned sample size, its results demonstrate a clinically meaningful effect size. Nevertheless, additional studies will be required to confirm these findings before they can be broadly incorporated into routine clinical practice.

Overall, the HOPE trial positions blood pressure control as a key component in optimizing stroke treatment after thrombectomy and opens the door to more precise strategies tailored to individual patients.

Source:

Institut de Recerca Sant Pau (Sant Pau Research Institute)

Journal reference:

Camps-Renom, P., et al. (2026) Personalized Blood Pressure Targeting After Endovascular Therapy for Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurology. DOI: 10.1001/jamaneurol.2026.1706. https://jamanetwork.com/journals/jamaneurology/fullarticle/2850074

Toward a paradigm shift in post-stroke management New HOPE trial explores individualized approach based on reperfusion pathophysiology

 Still NO PROTOCOL!  And no delivery of that non-existent protocol to all stroke hospitals1
OBVIOULY USELESS RESEARCH!

Toward a paradigm shift in post-stroke management: New HOPE trial explores individualized approach based on reperfusion pathophysiology

 Blood pressure management after thrombectomy for acute ischemic stroke may require a change in approach. The HOPE clinical trial—short for Hemodynamic Optimization of Cerebral Perfusion after Endovascular Therapy—led by the Sant Pau Research Institute (IR Sant Pau), has shown that adapting blood pressure targets to the degree of cerebral reperfusion significantly improves patients’ functional recovery without increasing the risk of complications.  “Until now, we have applied fairly uniform strategies after thrombectomy, but probably not all patients need the same approach,” says Dr. Pol Camps-Renom, head of the Cerebrovascular Diseases Research Group at IR Sant Pau and one of the study coordinators. “Our results suggest that adjusting blood pressure according to the degree of reperfusion can have a direct impact on recovery.” The findings, presented during a plenary session at the annual European Stroke Organisation conference—the leading European scientific society dedicated to stroke—and now published in JAMA Neurology position this work among the most important recent contributions in the stroke field. They have the potential to guide new hemodynamic management strategies after thrombectomy.  Rather than applying rigid targets, the key is to better understand each patient's physiology

Pol Camps-Renom

Mechanical thrombectomy has been a major advance in the treatment of large-vessel occlusion stroke because it can restore blood flow in previously blocked arteries. However, a well-known paradox remains in clinical practice: despite successful angiographic reperfusion, a substantial proportion of patients—around half—do not achieve satisfactory functional recovery in the medium term.(You blithering idiots don't understand the neuronal cascade of death then! Killing off hundreds of millions of neurons in the first week because you haven't stopped the neuronal cascade of death. You're all fired for absolute stupidity!)

 This phenomenon, known as “clinically ineffective reperfusion,” reflects the fact that reopening the vessel does not always result in effective restoration of cerebral perfusion at the tissue level. Mechanisms involved include reperfusion injury, microcirculatory dysfunction, loss of cerebral autoregulation, and hemorrhagic transformation, all of which can compromise brain tissue viability even after a technically successful intervention.  “Many times we can reopen the artery, but the brain tissue does not respond as expected,” explains Dr. Pol Camps-Renom. “The reason is that microvascular perfusion and autoregulatory mechanisms may be impaired, and this is where factors such as blood pressure become critical.” As a result, blood pressure control during the hours following thrombectomy has become a key component of clinical management because it directly influences the balance between maintaining adequate perfusion and avoiding hemorrhagic complications. However, the evidence available so far has been limited and, at times, contradictory. Previous trials based on uniform intensive blood pressure reduction strategies have not demonstrated consistent benefits and have even suggested possible adverse effects. 

Recommended article

News • Research, diagnostics, therapies

Focus on stroke

Strokes are among the most common cause of death worldwide and one of the most common causes of disability. Mortality rates are decreasing due to improving care. Nevertheless, experts expect the absolute number of cases to rise in view of the ageing population. Read more about current research and treatment options here.

 The HOPE trial introduces a different approach based on the concept that hemodynamic management should be adapted to each patient's physiological condition after thrombectomy. The study included 440 patients treated at 11 Spanish hospitals, who were randomly assigned either to a conventional strategy or to blood pressure management tailored to the degree of reperfusion achieved.  Unlike previous trials, HOPE implemented a differentiated strategy according to the final angiographic result. Patients with near-complete or complete reperfusion were treated with lower blood pressure targets to reduce the risk of reperfusion injury, whereas patients with incomplete reperfusion maintained higher blood pressure levels to preserve cerebral perfusion.  This approach recognizes that the brain may be in extremely diverse hemodynamic states, in which both excessively high blood pressure and overly aggressive reductions can be harmful. For this reason, the protocol included close monitoring during the first 72 hours, with dynamic treatment adjustments.  This strategy resulted in a significant and consistent improvement in clinical outcomes. At 90 days, 60.0% of patients in the intervention group achieved functional independence, compared with 47.1% in the control group, representing an absolute difference of 13.3 percentage points, a clinically meaningful improvement. In addition, the overall analysis showed a favorable trend toward better levels of recovery, reinforcing the consistency of the benefit.  In terms of safety, the strategy was associated with a lower incidence of hemorrhagic transformation, without increasing mortality or serious complications, confirming a favorable balance between efficacy and safety. “We have shown that it is possible to improve patient recovery without adding risk,” adds Dr. Joan Martí-Fàbregas, another investigator involved in the study. “This balance between efficacy and safety is probably one of the most relevant aspects of the findings.”  The results of the HOPE trial point toward a more individualized model for blood pressure control after thrombectomy. In a setting where previous trials had produced neutral or unfavorable results, this study introduces a physiology-based approach that can optimize the balance between perfusion and hemorrhagic risk.  Beyond its findings, HOPE provides key elements for the design of future studies, including the stratification of therapeutic targets and prolonged hemodynamic monitoring. The study also reinforces the idea that stroke treatment does not end with recanalization but continues during the hours that follow. “Rather than applying rigid targets, the key is to better understand each patient's physiology,” concludes Dr. Camps-Renom.  Although the trial was stopped before reaching the planned sample size, its results demonstrate a clinically meaningful effect size. Nevertheless, additional studies will be required to confirm these findings before they can be broadly incorporated into routine clinical practice.  Overall, the HOPE trial positions blood pressure control as a key component in optimizing stroke treatment after thrombectomy and opens the door to more precise strategies tailored to individual patients.  Source: Institut de Recerca Sant Pau 

BP Targets After Stroke Thrombectomy: Individualization Needed?

 Your doctor obviously hasn't though through blood pressure at all. Lowering too much means the penumbra will die quicker because of lack of oxygenated blood. Can your competent? doctor think at all about how to get you recovered? Ask him/her FOR EXACT SPECIFICS, doesn't have them is a sign of gross incompetence!

BP Targets After Stroke Thrombectomy: Individualization Needed?

Results of a new trial have re-awakened the possibility that blood pressure (BP) reduction following thrombectomy in patients with acute ischemic stroke (AIS) can be beneficial but with the caveat that BP targets may have to be individualized depending on patient-specific characteristics.

The HOPE trial showed that BP management intervention, with different targets for various levels of reperfusion achieved, improved functional outcomes after successful endovascular therapy.

This is the first clinical trial to demonstrate a benefit from BP reduction after thrombectomy; previous studies of intensive BP lowering — most conducted in Asia — showed either no benefit or even potential harm.

“Our trial reopens the debate about blood pressure lowering post-thrombectomy,” said lead investigator Pol Camps-Renom, MD, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Article Key Points

The HOPE trial suggests that individualized blood pressure targets post-thrombectomy may improve outcomes in acute ischemic stroke patients. The study found better functional outcomes and lower hemorrhagic transformation rates with tailored BP management, highlighting the need for personalized treatment strategies.

However, he cautioned that the findings should be considered hypothesis-generating rather than practice-changing, noting that other studies reinforcing the point that other trials have failed to show benefit with intensive BP lowering after thrombectomy but added that the results “definitely give information about key factors that can be incorporated into future trials.”

“I think the idea that one size will not fit all patients is probably the way forward and that blood pressures will be individualized based on patient characteristics in future. But it is too premature to act on these data at present,” he added.

The study was presented on May 6 at the European Stroke Organization Conference (ESOC) 2026.

Hazard if Not Fully Reperfused?

Compared with previous trials of intensive BP lowering after thrombectomy, the HOPE trial used different BP targets according to the degree of reperfusion achieved at the end of the procedure.

“We did this because we were concerned about blood circulation in patients with incomplete reperfusion,” Camps-Renom noted.

He cited data suggesting that patients with incomplete reperfusion after thrombectomy rely more heavily on collateral circulation to maintain cerebral blood flow, raising concerns that overly aggressive BP lowering in these patients could compromise collateral perfusion and prove harmful.

The trial was therefore designed with two different BP treatment targets. Conducted at 11 stroke centres in Spain, the HOPE trial enrolled patients with anterior circulation AIS due to intracranial large vessel occlusion within 24 hours of symptom onset who achieved successful recanalization after endovascular thrombectomy, defined as modified treatment in cerebral infarction (mTICI) 2b or higher.

A total of 440 patients were randomized to receive either protocol-driven or guideline-recommended BP management. In the intervention arm, systolic BP targets were individualized according to final reperfusion status.

For participants with good reperfusion after thrombectomy (mTICI 2c/3, equating to reperfusion of 90%-100%), a systolic BP target of 100-140 mg Hg was recommended. In contrast, those with incomplete reperfusion (mTICI 2b flow, indicating a reperfusion of 50%-90%), a target of 140-160 mm Hg was advised.

Randomization to the trial BP intervention protocol or standard guideline-based management began 1 hour after the final angiographic series, followed by an additional hour to achieve the assigned systolic BP target.

The intervention was then maintained for 72 hours and included antihypertensive therapy or vasopressor support, as needed.

Why HOPE Succeeded

Results showed that the primary endpoint — a favorable functional outcome (modified Rankin Scale score of 0-2 at 90 days) was achieved in 60.0% of patients in the intervention group vs 46.7% in the control group (OR, 1.71; 95% CI, 1.17-2.50; P = .005).